A predictive model of overall survival in patients with metastatic castration-resistant prostate cancer.

Metastatic castration resistant prostate cancer (mCRPC) is one of the most common cancers with a poor prognosis. To improve prognostic models of mCRPC, the Dialogue for Reverse Engineering Assessments and Methods (DREAM) Consortium organized a crowdsourced competition known as the Prostate Cancer DREAM Challenge. In the competition, data from four phase III clinical trials were utilized.

End-of-life pain medication among cancer patients in hospice settings.

Unlabelled: Cancer pain management in a hospice setting was studied in the present article. Drug treatments were studied at five time points: at the time of transfer to hospice, at 2nd day, two weeks, and two months following transfer to hospice care, as well as one day before death.

Patients And Methods: Records of 138 consecutive cancer patients treated in hospice in 2010 were studied regarding the drugs given during their stay.